Cybin Selects Anxiety Disorder Indications for Proprietary Psychedelic Molecule CYB004
Cybin Inc. (CYBN) announced that their new psychedelic molecule called CYB004 will target social anxiety disorder (SAD) and general anxiety disorder (GAD). Cybin’s Chief Clinical Officer says that anxiety disorders have increased three-fold during the COVID-19 pandemic, increasing the global market size to an estimated US$1.15B for SAD and US$2.99B for GAD. Cybin hopes to tap into this market, as many patients do not respond well to current anxiety medications such as SSRIs and SNRIs.